Putnam FL Investment Management Co. Sells 14,499 Shares of Charles River Laboratories Intl. Inc (NYSE:CRL)

Putnam FL Investment Management Co. trimmed its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 11.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 107,525 shares of the medical research company’s stock after selling 14,499 shares during the period. Charles River Laboratories Intl. comprises 1.1% of Putnam FL Investment Management Co.’s investment portfolio, making the stock its 29th largest position. Putnam FL Investment Management Co. owned 0.23% of Charles River Laboratories Intl. worth $11,769,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Lord Abbett & CO. LLC bought a new stake in shares of Charles River Laboratories Intl. during the second quarter valued at approximately $65,915,000. Mackenzie Financial Corp boosted its holdings in Charles River Laboratories Intl. by 81.7% in the third quarter. Mackenzie Financial Corp now owns 928,796 shares of the medical research company’s stock worth $100,329,000 after acquiring an additional 417,739 shares in the last quarter. TimesSquare Capital Management LLC bought a new stake in Charles River Laboratories Intl. in the third quarter worth $35,182,000. APG Asset Management N.V. raised its stake in shares of Charles River Laboratories Intl. by 261.2% in the fourth quarter. APG Asset Management N.V. now owns 368,800 shares of the medical research company’s stock worth $33,615,000 after purchasing an additional 266,700 shares during the last quarter. Finally, Koch Industries Inc. purchased a new position in shares of Charles River Laboratories Intl. in the second quarter worth $240,000. 97.13% of the stock is currently owned by institutional investors.

Charles River Laboratories Intl. Inc (NYSE:CRL) traded down $1.82 on Thursday, reaching $108.49. The company’s stock had a trading volume of 241,025 shares, compared to its average volume of 456,682. The stock has a market cap of $5,106.20, a P/E ratio of 43.43, a P/E/G ratio of 1.60 and a beta of 0.74. Charles River Laboratories Intl. Inc has a one year low of $86.25 and a one year high of $119.05. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.78 and a quick ratio of 1.62.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.26 by $0.14. The company had revenue of $478.50 million for the quarter, compared to the consensus estimate of $475.02 million. Charles River Laboratories Intl. had a return on equity of 26.14% and a net margin of 6.64%. Charles River Laboratories Intl.’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the business posted $1.21 EPS. equities analysts anticipate that Charles River Laboratories Intl. Inc will post 5.52 EPS for the current year.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 5,486 shares of Charles River Laboratories Intl. stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $109.53, for a total transaction of $600,881.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director C Richard Reese sold 10,227 shares of Charles River Laboratories Intl. stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total value of $1,047,244.80. Following the transaction, the director now owns 51,444 shares of the company’s stock, valued at approximately $5,267,865.60. The disclosure for this sale can be found here. Insiders have sold a total of 195,673 shares of company stock worth $2,644,046 in the last ninety days. Insiders own 2.20% of the company’s stock.

Several research analysts have recently weighed in on CRL shares. Argus began coverage on Charles River Laboratories Intl. in a research note on Wednesday, December 13th. They issued a “buy” rating and a $120.00 price target for the company. Bank of America reduced their price objective on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, November 10th. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price target for the company in a research report on Tuesday, October 24th. ValuEngine cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Finally, Evercore ISI assumed coverage on Charles River Laboratories Intl. in a research note on Thursday, January 18th. They issued an “in-line” rating and a $117.00 price objective for the company. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $114.85.

ILLEGAL ACTIVITY WARNING: This report was first reported by Week Herald and is the property of of Week Herald. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://weekherald.com/2018/02/15/putnam-fl-investment-management-co-sells-14499-shares-of-charles-river-laboratories-intl-inc-crl.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply